<DOC>
	<DOCNO>NCT02133118</DOCNO>
	<brief_summary>Next HbA1c , body weight regard important surrogate end-point trial investigate glucose-lowering agent . An increase weight could contribute worsen insulin resistance . Differences weight start glucose lower agent describe many randomize controlled trial ( RCTs ) . With prospective observational study , weight trajectory receive add-on therapy next metformin evaluate primary care patient good glycaemic control .</brief_summary>
	<brief_title>Weight Trajectory New Users Sulfonylureas Add Therapy Next Metformin .</brief_title>
	<detailed_description>This prospective cohort study part ZODIAC ( Zwolle Outpatient Diabetes project Integrating Available Care ) study , start 1998 prospective observational study include patient know T2DM treat primary care . The investigator aim investigate course bodyweight glycaemic control , year start specific SU 's , pioglitazone insulin add-on therapy , metformin treat primary care patient T2DM . As part process call benchmarking , dataset quality measure collect annually patient participate ZODIAC study patient 's visit practice nurse and/or general practitioner send investigator ' diabetes centre benchmarking research purpose year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>T2DM Treated primary care period 1998 2012 use metformin monotherapy subsequently receive addon therapy SU pioglitazone entire followup period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>New-user design</keyword>
	<keyword>Weight trajectory</keyword>
	<keyword>Add-on therapy</keyword>
	<keyword>Sulphonylureas .</keyword>
</DOC>